AzTrials
AzTrials

Adenocarcinoma of GastricPhase 1NCT07406984

Clinical Study of IM96 CAR-T Cell Therapy in Patients With Advanced Adenocarcinoma of Gastric/Esophagogastric Junction

A Phase 1 study testing IM96 CAR-T Cells in people with Adenocarcinoma of Gastric and Adenocarcinoma of Esophagogastric Junction, run by Beijing Immunochina Medical Science & Technology Co., Ltd. at 1 site in China.

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Sites and contacts
Official record
Search all trials

Trial summary

This study, a single-center, open, single-dose clinical study, was designed to evaluate the safety and efficacy of IM96 CAR-T cells in treating patients with advanced adenocarcinoma of gastric/esophagogastric junction Read more about this study

Who is it for?
Ages 18 to 75 years
What is being tested?
IM96 CAR-T Cells
Could I receive a placebo?
No, everyone receives an active treatment
How many people
18 participants
Where
1 siteChina
Study dates
5 Mar 2026to 31 Dec 2027
Phase
Phase 1
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 75 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • The age is 18 to 75 years (including boundary values) and the gender is not limited;
  • Patients with advanced locally inoperable or metastatic adenocarcinoma of the stomach/gastric esophageal junction diagnosed by pathohistology;
  • Patients with metastatic stomach/gastric esophageal junction who have failed or are intolerant to standard therapy;
  • Notes:
  • The standardized systemic treatment received by the patient must be in accordance with the Chinese Society of Clinical Oncology (CSCO) Guidelines for the Treatment of Gastric Cancer, 2025 Edition;
  • The standard prior treatment regimen should incorporate therapeutic strategies guided by relevant molecular biomarkers. Specifically, patients with HER2-positive tumors must have received HER2-targeted therapy;
Show all 17Show fewer
  • Claims of treatment intolerance: Patients who are unable to continue current effective systemic standardized treatment due to toxic side effects such as grade ≥3 vomiting, diarrhea, abdominal pain, bone marrow suppression, etc., and who do not accept refusal for financial and personal reasons;
  • Presence of at least one measurable lesion that meets RECIST 1.1 criteria;
  • Patients must provide a tumor sample within 2 years that meets the requirements (paraffin block or number of unstained sections that meet the testing requirements set by the Institute) that is positive for GUCY2C expression by immunohistochemistry;
  • Eastern cooperative oncology group (ECOG) score of 0-1;
  • Women of childbearing potential who have a negative blood pregnancy test prior to the start of the trial and who agree to use effective contraception during the trial and up to the last follow-up visit;male patients whose partners are of childbearing potential agree to use effective contraception during the trial and up to the last follow-up visit;
  • Laboratory tests should meet at least the indicators specified below:
  • Hemoglobin (Hb) ≥ 80 g/L; Neutrophil count (Absolute neutrophil count, ANC) ≥ 1.5 x 10^9/L; Platelet count (PLT) ≥ 75 x 10^9/L; Absolute lymphocyte value ≥ 0.6 x 10^9/L; Lymphocytes make up ≥10% of white blood cells; Creatinine clearance ≥60 ml/min; Alanine transaminase (ALT) and Aspartate aminotransferase (AST) ≤ 2.5 x ULN and total bilirubin (TBL) ≤ 1.5 x ULN (for elevations of ALT and AST that can be explained by hepatic aggression, the high limits for AST and ALT can be adjusted upward to 5-fold, and the high limit for TBL may be adjusted upward to 3-fold; Serum albumin ≥ 3.0 g/dL; Prolongation of prothrombinogen time ≤ 4s;
  • Left ventricular ejection fraction ≥ 50% with a normal ECG or an abnormal ECG that, in the judgment of the investigator, does not require treatment;
  • Oxygen saturation >92% in non-oxygenated state;
  • Vascular access is adequate for cell collection, and lines are available for patients with existing central venous catheters;
  • Those who voluntarily participate in the trial and sign the informed consent form.

Who cannot join

  • Presence of brain metastases;
  • Patients who have previously received or are awaiting an organ transplant;
  • Toxicity due to prior therapy not stabilized or recovered to ≤ grade 1 (except in cases judged by the investigator to be not clinically significant);
  • Plasmapheresis (e.g., pleural effusion, abdominal effusion, pericardial effusion) with symptoms of compression that cannot be controlled with treatment;
  • Autoimmune disease requiring systemic immunosuppressive therapy (e.g., Crohn's disease, rheumatoid arthritis, systemic lupus) within 2 years prior to the start of screening;
  • Lung diseases that the inversgaters determined were not suitable for inclusion in the study;
Show all 32Show fewer
  • Use of any of the following medications or treatments during the designated time period prior to cell collection:
  • Therapeutic doses of corticosteroids have been used within 7 days prior to cell collection. However, topical and inhaled steroids are permitted;
  • Received chemotherapeutic agents within 1 week prior to cell collection. Enrollment was allowed if the oral chemotherapeutic drug had passed at least 3 half-lives prior to cell collection;
  • Those who used drugs to stimulate bone marrow hematopoietic cell production within 5 days prior to cell collection;
  • Use of study drug within 4 weeks prior to cell collection.However, enrollment was allowed if the trial treatment was ineffective or the disease progressed during the trial and at least 5 half-lives had elapsed prior to cell collection;
  • Received interventional therapy, radiotherapy, ablation, and other localized treatments for the study disease within 4 weeks prior to cell collection;
  • Patients who have had major surgery or significant trauma within 4 weeks prior to cell collection or who are expected to require major surgery during the study period;
  • Received targeted drug treatment such as apatinib or fuyiquatine within one week prior to cell collection;
  • Received immunotherapy drugs such as anti-PD-1/PD-L1 within four weeks prior to cell collection;
  • Prior treatment with anti-GUCY2C target (unless GUCY2C target test remains positive);
  • Those who have received other cell therapy or genetically modified cell therapy in the past, such as TCR-T therapy, CAR-T therapy, etc;
  • Prior or clinically significant CNS disorders at screening, such as epilepsy, epileptic seizures, cerebrovascular disease (ischemia/hemorrhage/cerebral infarction), cerebral edema, reversible posterior leukoencephalopathy, paralysis, aphasia, stroke, severe brain injury,dementia, Parkinson's disease, cerebellar disorders, organic brain syndromes, or psychiatric disorders;
  • Chronic or active infection requiring systemic therapy and history of symptomatic viral infection that has not been completely cured. For example, Hepatitis B: patients who are positive for Hepatitis B surface antigen (HBsAg) and/or Hepatitis B core antibody (HBcAb) and whose peripheral blood HBV-DNA test is above the lower limit of detection;patients who are positive for Hepatitis C Virus Antibody (HCVAb) and whose peripheral blood HCV-RNA test is above the lower limit of detection; and patients infected with Human Immunodeficiency Virus (HIV), Syphilis;
  • Active EBV and cytomegalovirus, defined as patients with IgM antibodypositive or IgM antibody-negative but higher-than-normal EBV-DNA in EBV serum; and cytomegalovirus (CMV) seropositive or IgM antibodynegative but higher-than-normal CMV-DNA in serum;
  • Vaccination with live vaccine within 6 weeks prior to the start of screening;
  • Abnormalities of cardiac function include: long QTc syndrome or QTc interval >480 ms; complete left bundle branch block, degree II/III AV block; severe, uncontrolled arrhythmias requiring pharmacologic therapy; history of chronic congestive heart failure with NYHA class ≥3 (refer to Attachment 3) with a cardiac ejection fraction of less than 50% in the 6 months prior to screening; CTC AE ≥3 grade heart valve disease;myocardial infarction, cardiac angioplasty or stenting,unstable angina, history of severe pericardial disease, or other clinically significant cardiac disease within 6 months prior to screening;
  • Patients requiring anticoagulation therapy;
  • Requires long-term use of medications that can affect clotting (e.g.,aspirin, warfarin, etc.);
  • History of symptomatic deep vein thrombosis or pulmonary embolism within 6 months prior to initiation of screening;
  • Other untreated malignant tumors within the previous 5 years or concurrently, except cervical cancer in situ, basal cell carcinoma of the skin, and ductal carcinoma in situ of the breast;
  • Infections (fungal, bacterial, viral, or other) that require intravenous antimicrobial control or are uncontrollable, for simple urinary tract infections, and for bacterial pharyngitis, may be enrolled if the investigator evaluates that they can be controlled by curative treatment;
  • Patients with digestive tract obstruction;
  • The primary lesion exhibits a large ulcer, conferring a high risk of hemorrhage or perforation; alternatively, imaging studies (CT or MRI), with or without adjunctive gastroscopy, demonstrate transmural tumor invasion-i.e., infiltration across the full thickness of the gastric wall-thereby elevating the patient's risk of hemorrhage or perforation;
  • Patients present with unstable or active peptic ulcers, active gastrointestinal bleeding, or a history of major gastrointestinal bleeding within the preceding three months;
  • Concurrent enrollment in another clinical study, unless it is an observational (non-interventional) clinical study;
  • The presence of any factors affecting compliance with the protocol or the patient's unwillingness or inability to comply with the procedures required in the study protocol, as determined by the investigator.

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Fei Wu contact

8615801390058

wufei@imunopharm.com

Lin Shen, PhD contact

8610 88196561

doctorshenlin@sina.cn

China1 site

  • Beijing Cancer Hospital

    Beijing, Beijing Municipality, 100142

    Lin Shen, PhD, 8610 88196561, doctorshenlin@sina.cn

Other trials in China

About this study

Official title: A Phase I Clinical Study to Evaluate the Safety and Efficacy of IM96 CAR-T Cell Injection in Advanced Adenocarcinoma of Gastric/Esophagogastric Junction

This study, a single-center, open, single-dose clinical study, was designed to evaluate the safety and efficacy of IM96 CAR-T cells in treating patients with advanced adenocarcinoma of gastric/esophagogastric junction

Read the detailed description

This study is planned to enroll 18-24 patients with advanced adenocarcinoma of gastric/esophagogastric junction,using a modified "3+3" design for dose escalation, with 3 dose groups of 6×10^8 CAR-T cells ,12×10^8 CAR-T cells and 20×10^8 CAR-T cells. 3-6 subjects are planned to be enrolled in each dose group to assess their safety, and if the incidence of horizontal dose-limiting toxicity (DLT) is ≤1/6 within 28 days after transfusion in one dose group, the next dose group can be started. If the incidence of horizontal dose-limiting toxicity (DLT) in a dose group is ≤1/6 within 28 days after transfusion, transfusion of cells from the next dose group can be initiated.

This study will be divided into a screening period, a cell collection period, a chemotherapy pretreatment period, a return infusion and a follow-up period, and within 28 days of return infusion the investigator will assess whether a DLT (Dose limited toxicity) event has occurred to confirm the safety of this dose group.

Being tested
IM96 CAR-T Cells
Keywords
Advanced adenocarcinoma of gastric IM96 CAR-T, Advanced adenocarcinoma of esophagogastric junction IM96 CAR-T

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • IM96 CAR-T CellsBiological

    IM96 CAR-T Cells, 6×10^8 CAR-T cells, 12×10^8 CAR-T cells, 20×10^8 CAR-T cells, treatment follows a lymphodepletion.Drug: Fludarabine Recommendation: 30 mg/m^2 (D-5~D- 3), determined by tumor burden at baseline.Drug: Fludarabine Recommendation: 30 mg/m^2 (D-5~D-3), determined by tumor burden at baseline.Drug:Cyclophosphamide Recommendation: 300mg/ m^2 (D-5~D-3), determined by tumor burden at baseline.

Study groups in NCT07406984
Study groupRoleWhat they receive
IM96 CAR-T CellsExperimentalAfter preconditioning with chemotherapy, IM96 CAR-T Cells will be evaluated
Receives: Biological: IM96 CAR-T Cells

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Incidence of Treatment Related adverse events (AEs)

    Incidence of adverse events associated with IM96 CAR-T cell infusion within 28 days of IM96 CAR-T cell infusion,type, frequency, and severity of abnormal clinically significant vital signs, electrocardiograms, and laboratory tests examined, including dose-limiting toxicity

    Measured: Up to 28 days after CAR-T cell infusion

Secondary outcomes (10)

  1. Objective remission rate (ORR)

    Objective remission rate (ORR) after infusion

    Measured: At 28 days, 3 months, 6 months and 12 months after CAR-T cell infusion

  2. Progression-free survival (PFS)

    Progression-free survival (PFS) after infusion

    Measured: At 28 days, 3 months, 6 months and 12 months after CAR-T cell infusion

  3. Disease control rate (DCR)

    Disease control rate (DCR) after infusion

    Measured: At 28 days, 3 months, 6 months and 12 months after CAR-T cell infusion

  4. Duration of response (DOR)

    Duration of response (DOR) after infusion

    Measured: At 28 days, 3 months, 6 months and 12 months after CAR-T cell infusion

  5. Overall survival (OS)

    Overall survival (OS) after infusion

    Measured: At 28 days, 3 months, 6 months and 12 months after CAR-T cell infusion

  6. AUC (Area Under Curve) 0-D90

    AUC 0-D90 of IM96 CAR-T cells in vivo (peripheral blood) after infusion

    Measured: Up to 90 days after CAR-T cell infusion

  7. Cmax (Peak Concentration)

    Peak Concentrationof IM96 CAR-T cells in vivo (peripheral blood) after infusion

    Measured: Up to 28 days after CAR-T cell infusion

  8. Tmax (Peak Time)

    Peak Time of IM96 CAR-T cells in vivo (peripheral blood) after infusion

    Measured: Up to 28 days after CAR-T cell infusion

  9. Tumor markers CA19-9

    The changes of tumor markers CA19-9 before and after IM96 CAR-T cell infusion

    Measured: At 28 days, 3 months, 6 months and 12 months after CAR-T cell infusion

  10. Tumor markers CEA

    The changes of tumor markers CEA before and after IM96 CAR-T cell infusion

    Measured: At 28 days, 3 months, 6 months and 12 months after CAR-T cell infusion

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted12 Feb 2026
  2. Study start5 Mar 2026 (estimated)
  3. Primary completion5 May 2027 (estimated)
  4. Study completion31 Dec 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
18 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07406984
Sponsor's protocol ID
YMSZ9603
Status last verified
Feb 2026
First submitted
6 Feb 2026
Last updated
13 Feb 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A Phase 1 study testing IM96 CAR-T Cells in people with Adenocarcinoma of Gastric and Adenocarcinoma of Esophagogastric Junction, run by Beijing Immunochina Medical Science & Technology Co., Ltd. at 1 site in China.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 17 inclusion and 32 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: opening soon, as of the sponsor's last update on 13 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Fei Wu (8615801390058, wufei@imunopharm.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Incidence of Treatment Related adverse events (AEs) (time frame: Up to 28 days after CAR-T cell infusion). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07406984.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Feb 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in